Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2010, Article ID 167984, 7 pages
http://dx.doi.org/10.4061/2010/167984
Review Article

Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease

Department of Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan

Received 27 August 2010; Accepted 28 October 2010

Academic Editor: R. Khanna

Copyright © 2010 Kosaku Nitta. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Yamashita, M. Yoshioka, and N. Itoh, “Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain,” Biochemical and Biophysical Research Communications, vol. 277, no. 2, pp. 494–498, 2000. View at Publisher · View at Google Scholar · View at PubMed
  2. M. Riminucci, M. T. Collins, and M. T. Collins, “FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting,” Journal of Clinical Investigation, vol. 112, no. 5, pp. 683–692, 2003. View at Publisher · View at Google Scholar
  3. T. Yamashita, “Structural and biochemical properties of fibroblast growth factor 23,” Therapeutic Apheresis and Dialysis, vol. 9, no. 4, pp. 313–318, 2005. View at Google Scholar
  4. L. D. Quarles, “Endocrine functions of bone in mineral metabolism regulation,” Journal of Clinical Investigation, vol. 118, no. 12, pp. 3820–3828, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. X.-Y. Bai, D. Miao, D. Goltzman, and A. C. Karaplis, “The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency,” Journal of Biological Chemistry, vol. 278, no. 11, pp. 9843–9849, 2003. View at Publisher · View at Google Scholar · View at PubMed
  6. T. Larson, R. Marsell, and R. Marsell, “Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis,” Endocrinology, vol. 145, no. 7, pp. 3087–3094, 2004. View at Publisher · View at Google Scholar · View at PubMed
  7. T. Shimada, I. Urakawa, and I. Urakawa, “FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa,” Biochemical and Biophysical Research Communications, vol. 314, no. 2, pp. 409–414, 2004. View at Publisher · View at Google Scholar
  8. X. Bai, D. Miao, J. Li, D. Goltzman, and A. C. Karaplis, “Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders,” Endocrinology, vol. 145, no. 11, pp. 5269–5279, 2004. View at Publisher · View at Google Scholar · View at PubMed
  9. D. Sitara, M. S. Razzaque, and M. S. Razzaque, “Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice,” Matrix Biology, vol. 23, no. 7, pp. 421–432, 2004. View at Publisher · View at Google Scholar · View at PubMed
  10. T. Shimada, M. Kakitani, and M. Kakitani, “Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism,” Journal of Clinical Investigation, vol. 113, no. 4, pp. 561–568, 2004. View at Publisher · View at Google Scholar
  11. T. Shimada, H. Hasegawa, and H. Hasegawa, “FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis,” Journal of Bone and Mineral Research, vol. 19, no. 3, pp. 429–435, 2004. View at Publisher · View at Google Scholar · View at PubMed
  12. H. Segawa, E. Kawakami, and E. Kawakami, “Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter,” Pflugers Archiv European Journal of Physiology, vol. 446, no. 5, pp. 585–592, 2003. View at Publisher · View at Google Scholar · View at PubMed
  13. A. Khosravi, C. M. Cutler, M. H. Kelly et al., “Determination of the elimination half-life of fibroblast growth factor-23,” Journal of Clinical Endocrinology and Metabolism, vol. 92, pp. 2374–2377, 2007. View at Google Scholar
  14. Y. Yamazaki, R. Okazaki, and R. Okazaki, “Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 11, pp. 4957–4960, 2002. View at Publisher · View at Google Scholar
  15. Y. Imanishi, M. Inaba, and M. Inaba, “FGF-23 in patients with end-stage renal disease on hemodialysis,” Kidney International, vol. 65, no. 5, pp. 1943–1946, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M. Kuro-o, Y. Matsumura, and Y. Matsumura, “Mutation of the mouse klotho gene leads to a syndrome resembling ageing,” Nature, vol. 390, no. 6655, pp. 45–51, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. H. Tsujikawa, Y. Kurotaki, T. Fujimori, K. Fukuda, and Y.-I. Nabeshima, “Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system,” Molecular Endocrinology, vol. 17, no. 12, pp. 2393–2403, 2003. View at Publisher · View at Google Scholar · View at PubMed
  18. M. S. Razzaque, D. Sitara, T. Taguchi, R. St-Arnaud, and B. Lanske, “Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process,” FASEB Journal, vol. 20, no. 6, pp. 720–722, 2006. View at Publisher · View at Google Scholar · View at PubMed
  19. T. Nakatani, B. Sarraj, and B. Sarraj, “In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis,” FASEB Journal, vol. 23, no. 2, pp. 433–441, 2009. View at Publisher · View at Google Scholar · View at PubMed
  20. H. Kurosu, Y. Ogawa, and Y. Ogawa, “Regulation of fibroblast growth factor-23 signaling by Klotho,” Journal of Biological Chemistry, vol. 281, no. 10, pp. 6120–6123, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. Mohammadi, S. K. Olsen, and O. A. Ibrahimi, “Structural basis for fibroblast growth factor receptor activation,” Cytokine and Growth Factor Reviews, vol. 16, pp. 107–137, 2005. View at Publisher · View at Google Scholar · View at PubMed
  22. T. Krajisnik, P. Björklund, and P. Björklund, “Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells,” Journal of Endocrinology, vol. 195, no. 1, pp. 125–131, 2007. View at Publisher · View at Google Scholar · View at PubMed
  23. T. Kawata, Y. Imanishi, K. Kobayashi, T. Miki, A. Arnold, M. Inaba, and Y. Nishizawa, “Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism,” Journal of the American Society of Nephrology, vol. 18, no. 10, pp. 2683–2688, 2007. View at Publisher · View at Google Scholar · View at PubMed
  24. O. Gutiérrez, T. Isakova, and T. Isakova, “Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease,” Journal of the American Society of Nephrology, vol. 16, no. 7, pp. 2205–2215, 2005. View at Publisher · View at Google Scholar · View at PubMed
  25. M. Cozzolino, A. Galassi, M. Gallieni, and D. Brancaccio, “Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol,” Current Vascular Pharmacology, vol. 6, no. 2, pp. 148–153, 2008. View at Publisher · View at Google Scholar
  26. N. Nagano, S. Miyata, M. Abe, N. Kobayashi, S. Wakita, T. Yamashita, and M. Wada, “Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats,” Kidney International, vol. 69, no. 3, pp. 531–537, 2006. View at Publisher · View at Google Scholar · View at PubMed
  27. D. Fliser, B. Kollerits, and B. Kollerits, “Fibroblast Growth Factor 23 (FGF23) predicts progression of chronic kidney disease. The Mild to Moderate Kidney Disease (MMKD) study,” Journal of the American Society of Nephrology, vol. 18, no. 9, pp. 2601–2608, 2007. View at Publisher · View at Google Scholar · View at PubMed
  28. T. Larsson, U. Nisbeth, Ö. Ljunggren, H. Jüppner, and K. B. Jonsson, “Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers,” Kidney International, vol. 64, no. 6, pp. 2272–2279, 2003. View at Publisher · View at Google Scholar · View at PubMed
  29. N. Koh, T. Fujimori, and T. Fujimori, “Severely reduced production of klotho in human chronic renal failure kidney,” Biochemical and Biophysical Research Communications, vol. 280, no. 4, pp. 1015–1020, 2001. View at Publisher · View at Google Scholar · View at PubMed
  30. S. Seiler, G. H. Heine, and D. Fliser, “Clinical relevance of FGF-23 in chronic kidney disease,” Kidney International, no. 114, supplement, pp. S34–S42, 2009. View at Google Scholar · View at Scopus
  31. C. M. Giachelli, “Vascular calcification mechanisms,” Journal of the American Society of Nephrology, vol. 15, no. 12, pp. 2959–2964, 2004. View at Publisher · View at Google Scholar · View at PubMed
  32. V. Lavi-Moshayoff, J. Silver, and T. Naveh-Many, “Human PTH gene regulation in vivo using transgenic mice,” American Journal of Physiology, vol. 297, no. 3, pp. F713–F719, 2009. View at Publisher · View at Google Scholar · View at PubMed
  33. M. S. Razzaque and B. Lanske, “The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis,” Journal of Endocrinology, vol. 194, no. 1, pp. 1–10, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. R. N. Foley, A. M. Murray, S. Li, C. A. Herzog, A. M. McBean, P. W. Eggers, and A. J. Collins, “Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999,” Journal of the American Society of Nephrology, vol. 16, no. 2, pp. 489–495, 2005. View at Publisher · View at Google Scholar · View at PubMed
  35. J. Blacher , A. P. Guerin, B. Pannier, S. J. Marchais, and G. M. London, “Arterial calcification, arterial stiffness, and cardiovascular risk I end-stage renal disease,” Hypertension, vol. 38, pp. 938–942, 2001. View at Google Scholar
  36. A. Y.-M. Wang, M. Wang, J. Woo, C. W.-K. Lam, P. K.-T. Li, S.-F. Lui, and J. E. Sanderson, “Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study,” Journal of the American Society of Nephrology, vol. 14, no. 1, pp. 159–168, 2003. View at Publisher · View at Google Scholar
  37. S. Okuno, E. Ishimura, and E. Ishimura, “Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients,” American Journal of Kidney Diseases, vol. 49, no. 3, pp. 417–425, 2007. View at Publisher · View at Google Scholar · View at PubMed
  38. M. K. Sigrist, M. W. Taal, P. Bungay, and C. W. McIntyre, “Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 6, pp. 1241–1248, 2007. View at Publisher · View at Google Scholar · View at PubMed
  39. T. Ogawa, H. Ishida, and H. Ishida, “Progression of aortic arch calcification and all-cause and cardiovascular mortality in chronic hemodialysis patients,” International Urology and Nephrology, vol. 42, no. 1, pp. 187–194, 2010. View at Publisher · View at Google Scholar · View at PubMed
  40. G. M. London, “Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function,” Journal of the American Society of Nephrology, vol. 14, supplement 4, pp. S305–S309, 2003. View at Google Scholar
  41. K. Nitta, T. Akiba, and T. Akiba, “Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients,” Hypertension Research, vol. 27, no. 1, pp. 47–52, 2004. View at Publisher · View at Google Scholar
  42. M. Cozzolino, S. Mazzaferro, F. Pugliese, and D. Brancaccio, “Vascular calcification and uremia: what do we know?” American Journal of Nephrology, vol. 28, no. 2, pp. 339–346, 2008. View at Publisher · View at Google Scholar · View at PubMed
  43. A. Covic, P. Kothawala, S. Robbins et al., “Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 24, no. 5, pp. 1506–1523, 2009. View at Publisher · View at Google Scholar · View at PubMed
  44. S. Jono, M. D. McKee, and M. D. McKee, “Phosphate regulation of vascular smooth muscle cell calcification,” Circulation Research, vol. 87, no. 7, pp. E10–E17, 2000. View at Google Scholar
  45. X. Li, H. Y. Yang, and C. M. Giachelli, “Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification,” Circulation Research, vol. 98, no. 7, pp. 905–912, 2006. View at Publisher · View at Google Scholar · View at PubMed
  46. H. Yang, G. Curinga, and C. M. Giachelli, “Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro,” Kidney International, vol. 66, no. 6, pp. 2293–2299, 2004. View at Publisher · View at Google Scholar · View at PubMed
  47. D. Sitara, M. S. Razzaque, R. St-Armaud et al., “Geetic ablation of vitamin D activation pathway reverses biochemical and skeletal anormalies in Fgf-23 null animals,” American Journal of Pathology, vol. 169, pp. 2161–2170, 2006. View at Google Scholar
  48. A. Aoki, F. Kojima, K. Uchida, Y. Tanaka, and K. Nitta, “Associations between vascular calcification, arterial stiffness and bone mineral density in chronic hemodialysis patients,” Geriatrics and Gerontology International, vol. 9, no. 3, pp. 246–252, 2009. View at Publisher · View at Google Scholar · View at PubMed
  49. P. A. Narcovitz, H. H. Tran, B. A. Franklin et al., “Usefulness of bone mineral density to predict significant coronary artery disease,” American Journal of Cardiology, vol. 96, pp. 1059–1063, 2005. View at Google Scholar
  50. B. Lanske and M. S. Razzaque, “Mineral metabolism and aging: the fibroblast growth factor 23 enigma,” Current Opinion in Nephrology and Hypertension, vol. 16, no. 4, pp. 311–318, 2007. View at Publisher · View at Google Scholar · View at PubMed
  51. O. M. Gutiérrez, M. Mannstadt, and M. Mannstadt, “Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis,” New England Journal of Medicine, vol. 359, no. 6, pp. 584–592, 2008. View at Publisher · View at Google Scholar · View at PubMed
  52. M. M. Nasrallah, A. R. El-Shehaby, M. M. Salem, N. A. Osman, E. El Sheikh, and U. A. Sharaf El Din, “Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 25, no. 8, pp. 2679–2685, 2010. View at Publisher · View at Google Scholar · View at PubMed
  53. G. Jean, J.-C. Terrat, T. Vanel, J.-M. Hurot, C. Lorriaux, B. Mayor, and C. Chazot, “High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 24, no. 9, pp. 2792–2796, 2009. View at Publisher · View at Google Scholar · View at PubMed
  54. M. Inaba, S. Okuno, and S. Okuno, “Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients,” Osteoporosis International, vol. 17, no. 10, pp. 1506–1513, 2006. View at Publisher · View at Google Scholar · View at PubMed
  55. G. Jean, E. Bresson, and E. Bresson, “Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences,” Nephrology Dialysis Transplantation, vol. 24, no. 3, pp. 948–955, 2009. View at Publisher · View at Google Scholar · View at PubMed
  56. S. Nakanishi, J. J. Kazama, and J. J. Kazama, “Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients,” Kidney International, vol. 67, no. 3, pp. 1171–1178, 2005. View at Publisher · View at Google Scholar · View at PubMed
  57. O. M. Gutiérrez, J. L. Januzzi, and J. L. Januzzi, “Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease,” Circulation, vol. 119, no. 19, pp. 2545–2552, 2009. View at Publisher · View at Google Scholar · View at PubMed
  58. M. A. I. Mirza, A. Larsson, L. Lind, and T. E. Larsson, “Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community,” Atherosclerosis, vol. 205, no. 2, pp. 385–390, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus